2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗

2018-12-18 国外神经外科相关专家小组(统称) BMJ. 2018 Dec 18;363:k5130.

对于短暂性脑缺血发作(TIA)或轻型缺血性卒中患者,24h内接受阿司匹林联合氯吡格雷的双重抗血小板治疗与阿司匹林单药治疗相比,能否更能减少卒中复发和死亡率? 就该问题,近日,BMJ杂志发表了《阿司匹林+氯吡格雷双重抗血小板治疗治疗高危短暂性脑缺血发作和急性轻型缺血性卒中患者:临床实践指南》。指南推荐,对于急性轻型缺血性卒中或高危TIA患者,应在症状发作后24小时内尽快给予氯吡格雷联合阿司匹林双联抗

中文标题:

2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗

英文标题:

Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.

发布日期:

2018-12-18

简要介绍:

对于短暂性脑缺血发作(TIA)或轻型缺血性卒中患者,24h内接受阿司匹林联合氯吡格雷的双重抗血小板治疗与阿司匹林单药治疗相比,能否更能减少卒中复发和死亡率? 就该问题,近日,BMJ杂志发表了《阿司匹林+氯吡格雷双重抗血小板治疗治疗高危短暂性脑缺血发作和急性轻型缺血性卒中患者:临床实践指南》。指南推荐,对于急性轻型缺血性卒中或高危TIA患者,应在症状发作后24小时内尽快给予氯吡格雷联合阿司匹林双联抗血小板治疗,并且持续治疗10-21天。 

拓展指南:阿司匹林相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗)] GetToolGuiderByIdResponse(projectId=1, id=bc4e71c00169eaf6, title=2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗, enTitle=Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline., guiderFrom=BMJ. 2018 Dec 18;363:k5130., authorId=null, author=, summary=对于短暂性脑缺血发作(TIA)或轻型缺血性卒中患者,24h内接受阿司匹林联合氯吡格雷的双重抗血小板治疗与阿司匹林单药治疗相比,能否更能减少卒中复发和死亡率? 就该问题,近日,BMJ杂志发表了《阿司匹林+氯吡格雷双重抗血小板治疗治疗高危短暂性脑缺血发作和急性轻型缺血性卒中患者:临床实践指南》。指南推荐,对于急性轻型缺血性卒中或高危TIA患者,应在症状发作后24小时内尽快给予氯吡格雷联合阿司匹林双联抗, cover=, journalId=null, articlesId=null, associationId=1328, associationName=国外神经外科相关专家小组(统称), associationIntro=, copyright=0, guiderPublishedTime=Tue Dec 18 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>对于短暂性脑缺血发作(TIA)或轻型缺血性卒中患者,24h内接受阿司匹林联合氯吡格雷的双重抗血小板治疗与阿司匹林单药治疗相比,能否更能减少卒中复发和死亡率? 就该问题,近日,BMJ杂志发表了《阿司匹林+氯吡格雷双重抗血小板治疗治疗高危短暂性脑缺血发作和急性轻型缺血性卒中患者:临床实践指南》。指南推荐,对于急性轻型缺血性卒中或高危TIA患者,应在症状发作后24小时内尽快给予氯吡格雷联合阿司匹林双联抗血小板治疗,并且持续治疗10-21天。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>阿司匹林</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=8792e1c001ae80b5" title="阿司匹林在动脉粥样硬化性心血管疾病中的临床应用:中国专家共识(2016)" target=_blank>阿司匹林在动脉粥样硬化性心血管疾病中的临床应用:中国专家共识(2016)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1a9631c001281844" title="2015 阿司匹林用于心血管疾病一级预防的专家建议" target=_blank>2015 阿司匹林用于心血管疾病一级预防的专家建议</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c8ae31c0012a5851" title="2016 ESC意见书:非阿司匹林非甾体抗炎药物的心血管安全性" target=_blank>2016 ESC意见书:非阿司匹林非甾体抗炎药物的心血管安全性</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e7e2c1c00122e116" title="2016 USPSTF建议声明:阿司匹林用于心血管疾病和结直肠癌的一级预防" target=_blank>2016 USPSTF建议声明:阿司匹林用于心血管疾病和结直肠癌的一级预防</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e7a431c00110e712" title="2014 USPSTF 小剂量阿司匹林预防孕妇先兆子痫建议声明" target=_blank>2014 USPSTF 小剂量阿司匹林预防孕妇先兆子痫建议声明</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E9%98%BF%E5%8F%B8%E5%8C%B9%E6%9E%97" target=_blank>有关阿司匹林更多指南</a></ul>, tagList=[TagDto(tagId=3482, tagName=短暂性脑缺血发作), TagDto(tagId=86262, tagName=轻型缺血性卒中), TagDto(tagId=659, tagName=阿司匹林), TagDto(tagId=504, tagName=氯吡格雷), TagDto(tagId=14625, tagName=双抗治疗)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11329, appHits=782, showAppHits=6, pcHits=6816, showPcHits=5935, likes=200, shares=14, comments=4, approvalStatus=1, publishedTime=Wed Feb 06 20:55:58 CST 2019, publishedTimeString=2018-12-18, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Feb 06 20:55:58 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 11:53:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗)])
2018 临床实践指南:急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2113420, encodeId=f1532113420b1, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=221d8145660, createdName=ms6000000756412384, createdTime=Tue Feb 07 11:58:02 CST 2023, time=2023-02-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1186814, encodeId=944f11868141c, content=学习了,真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011067, encodeId=277e101106ead, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:06:50 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2023-02-07 ms6000000756412384 来自四川省

    很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2113420, encodeId=f1532113420b1, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=221d8145660, createdName=ms6000000756412384, createdTime=Tue Feb 07 11:58:02 CST 2023, time=2023-02-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1186814, encodeId=944f11868141c, content=学习了,真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011067, encodeId=277e101106ead, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:06:50 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2022-01-21 ms1000001107271726

    学习了,真好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2113420, encodeId=f1532113420b1, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=221d8145660, createdName=ms6000000756412384, createdTime=Tue Feb 07 11:58:02 CST 2023, time=2023-02-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1186814, encodeId=944f11868141c, content=学习了,真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:28 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011067, encodeId=277e101106ead, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b594200092, createdName=13d7108bm77暂无昵称, createdTime=Tue Aug 24 18:06:50 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2021-08-24 13d7108bm77暂无昵称

    0